Clinical Trial Results:
Prospective, historically controlled study to evaluate the efficacy and safety of a new pediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas’ disease
Summary
|
|
EudraCT number |
2022-001504-17 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
10 Aug 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
31 Aug 2022
|
First version publication date |
31 Aug 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
16027
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02625974 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Bayer AG
|
||
Sponsor organisation address |
Kaiser-Wilhelm-Allee, Leverkusen, Germany, 51368
|
||
Public contact |
Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
|
||
Scientific contact |
Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-003134-PIP01-21 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
10 Aug 2021
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
10 Aug 2021
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The study consists of two parts: Part 1 (CHICO) comprised the treatment with nifurtimox including the 1-year follow up, and Part 2 (CHICO SECURE) comprises additional 3 years of follow-up after end of Part 1.
The primary objective of Part 1 was to assess the superiority of a 60-day regimen of nifurtimox to historical untreated control at the 12-month follow-up (360 days from end of treatment [EOT]) as:
- sero-reduction (defined as a ≥20% reduction in OD compared to baseline in subjects ≥8 months to <18 years of age at randomization; or
- sero-conversion (defined as negative IgG concentration) in all subjects
The primary objective of Part 2 was to assess the incidence of seronegative conversion in subjects who were randomized and received at least one dose of the 60-day nifurtimox treatment regimen in Part 1, compared to an external control group of historical placebo patients with Chagas’ disease at the 4-year follow-up.
|
||
Protection of trial subjects |
The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent form was read by and explained to all subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
27 Jan 2016
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
4 Years | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 178
|
||
Country: Number of subjects enrolled |
Bolivia, Plurinational State of: 62
|
||
Country: Number of subjects enrolled |
Colombia: 90
|
||
Worldwide total number of subjects |
330
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
7
|
||
Infants and toddlers (28 days-23 months) |
37
|
||
Children (2-11 years) |
146
|
||
Adolescents (12-17 years) |
140
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Part 1 of the study was conducted from 27 JAN 2016 (First subject first visit) to 25 JUL 2018 (Last subject last visit) in Argentina, Bolivia and Colombia. Part 2 of the study was conducted from 26 SEP 2018 (First subject first visit) to 10 AUG 2021 (Last subject last visit) in Argentina, Bolivia and Colombia. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Part 1: 330 subjects who were eligible to participate in the study were randomized in a 2:1 ratio to either a 60-Day or 30-Day regimen with nifurtimox tablets. 308 subjects completed treatment in Part 1, and 318 subjects completed Part 1. Part 2: Of the 318 subjects completed Part 1, 295 subjects were included in Part 2. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Part 1
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Investigator, Subject | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Nifurtimox 60 days / Arm 1 | ||||||||||||||||||
Arm description |
Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Nifurtimox
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Nifurtimox tablets administered 3 times daily for 60 days (Days 1 – 60, active treatment, Treatment Group 1)
|
||||||||||||||||||
Arm title
|
Nifurtimox 30 days, then Placebo 30 days / Arm 2 | ||||||||||||||||||
Arm description |
Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Nifurtimox
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Nifurtimox tablets administered 3 times daily for 30 days (Days 1 – 30, active treatment; Treatment Group 2)
|
||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Matching placebo administered 3 times daily for 30 days (Days 31 – 60, placebo; Treatment Group 2)
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Part 2
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Nifurtimox 60 days / Arm 1 | ||||||||||||||||||
Arm description |
Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment) Treatment administered in Part 1; no study drug was administered in Part 2 | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Nifurtimox
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Nifurtimox tablets administered 3 times daily for 60 days (Days 1 – 60, active treatment, Treatment Group 1)
|
||||||||||||||||||
Arm title
|
Nifurtimox 30 days, then Placebo 30 days / Arm 2 | ||||||||||||||||||
Arm description |
Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo) Treatment administered in Part 1; no study drug was administered in Part 2 | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Nifurtimox
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Nifurtimox tablets administered 3 times daily for 30 days (Days 1 – 30, active treatment; Treatment Group 2)
|
||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Matching placebo administered 3 times daily for 30 days (Days 31 – 60, placebo; Treatment Group 2)
|
||||||||||||||||||
|
|||||||||||||||||||
Notes [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: Of the 318 subjects completed Part 1, 295 subjects were included in Part 2 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nifurtimox 60 days / Arm 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nifurtimox 30 days, then Placebo 30 days / Arm 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Nifurtimox 60 days / Arm 1
|
||
Reporting group description |
Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment) | ||
Reporting group title |
Nifurtimox 30 days, then Placebo 30 days / Arm 2
|
||
Reporting group description |
Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo) | ||
Reporting group title |
Nifurtimox 60 days / Arm 1
|
||
Reporting group description |
Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment) Treatment administered in Part 1; no study drug was administered in Part 2 | ||
Reporting group title |
Nifurtimox 30 days, then Placebo 30 days / Arm 2
|
||
Reporting group description |
Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo) Treatment administered in Part 1; no study drug was administered in Part 2 | ||
Subject analysis set title |
Nifurtimox 60 days Reactive Detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Reactive Conventional Serologic Testing and Detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 60 days Reactive Non-detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Reactive Conventional Serologic Testing and Non-detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 60 days Non-reactive Detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 60 days Non-reactive Non-detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Non-detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 60 days Reactive Non evaluable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Reactive Conventional Serologic Testing and Non evaluable qPCR
|
||
Subject analysis set title |
Nifurtimox 60 days Reactive qPCR Missing
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Reactive Conventional Serologic Testing and missing qPCR
|
||
Subject analysis set title |
Nifurtimox 30 days Reactive Detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Reactive Conventional Serologic Testing and Detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 30 days Reactive Non-detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Reactive Conventional Serologic Testing and Non-detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 30 days Non-reactive Detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 30 days Non-reactive Non-detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Non-detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 30 days Reactive Non evaluable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Reactive Conventional Serologic Testing and Non evaluable qPCR
|
||
Subject analysis set title |
Nifurtimox 30 days Missing Conventional testing Non-detectable
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with missing Conventional Serologic Testing and Non-detectable qPCR
|
||
Subject analysis set title |
Nifurtimox 60 days Reactive and Reactive
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing
|
||
Subject analysis set title |
Nifurtimox 60 days Reactive and Non-reactive
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing
|
||
Subject analysis set title |
Nifurtimox 60 days Non-reactive and Reactive
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing
|
||
Subject analysis set title |
Nifurtimox 60 days Non-reactive and Non-reactive
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing
|
||
Subject analysis set title |
Nifurtimox 30 days Reactive and Reactive
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing
|
||
Subject analysis set title |
Nifurtimox 30 days Reactive and Non-reactive
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing
|
||
Subject analysis set title |
Nifurtimox 30 days Non-reactive and Reactive
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing
|
||
Subject analysis set title |
Nifurtimox 30 days Non-reactive and Non-reactive
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing
|
||
Subject analysis set title |
Non-reactive ELISA and Non-reactive IHA
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: Non-reactive
IHA results: Non-reactive
|
||
Subject analysis set title |
Non-reactive ELISA and reactive IHA decrease
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: Non-reactive
IHA results: reactive with decreasing in titers
|
||
Subject analysis set title |
Non-react ELISA and react IHA Nochange
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: Non-reactive
IHA results: reactive without change in titers
|
||
Subject analysis set title |
Reactive ELISA: Sero-reduction and Non-react IHA
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: reactive, Sero-reduction
IHA results: Non-reactive
|
||
Subject analysis set title |
Reactive ELISA: Sero reduction and reactive IHA decrease
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: reactive, Sero-reduction
IHA results: reactive with decreasing in titers
|
||
Subject analysis set title |
Reactive ELISA: Sero-reduction and reactive IHA Nochange
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: reactive, Sero-reduction
IHA results: reactive without Change in titers
|
||
Subject analysis set title |
Reactive ELISA: Others and Non-reactive IHA
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: reactive, Others
IHA results: Non-reactive
|
||
Subject analysis set title |
Reactive ELISA: Others and react IHA decrease
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: reactive, Other
IHA: reactive with decreasing in titers
|
||
Subject analysis set title |
Reactive ELISA: Others and react IHA Nochange
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: reactive, Other
IHA results: reactive without Change in titers
|
||
Subject analysis set title |
Reactive ELISA: Others and Missing IHA
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
ELISA results: reactive, Others
IHA results: Missing
|
||
Subject analysis set title |
Cure and Non reactive/reactive decreasing
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Elisa results: Cure
IHA results: Non reactive or reactive but decreasing in titer
|
||
Subject analysis set title |
Cure and reactive non-decreasing
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Elisa results: Cure
IHA results: reactive but non-decreasing in titer
|
||
Subject analysis set title |
No Cure and Non reactive/reactive decreasing
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Elisa results: No Cure
IHA results: Non reactive or reactive but decreasing in titer
|
||
Subject analysis set title |
No Cure and reactive non-decreasing
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Elisa results: No Cure
IHA results: reactive but non-decreasing in titer
|
||
Subject analysis set title |
No Cure and Missing IHA Testing
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Elisa results: No Cure
IHA results: Missing
|
||
Subject analysis set title |
Nifurtimox 60 days: Chagas-related cardiomyopathy = Yes
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Serological response measured by two types of assays and ECG evaluation for signs of established Chagas-related cardiomyopathy by visit
|
||
Subject analysis set title |
Nifurtimox 60 days: Chagas-related cardiomyopathy = No
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Serological response measured by two types of assays and ECG evaluation for signs of established Chagas-related cardiomyopathy by visit
|
||
Subject analysis set title |
Nifurtimox 60 days: Chagas-related cardiomyopathy = Missing
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Serological response measured by two types of assays and ECG evaluation for signs of established Chagas-related cardiomyopathy by visit
|
||
Subject analysis set title |
Nifurtimox 30 days: Chagas-related cardiomyopathy = Yes
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Serological response measured by two types of assays and ECG evaluation for signs of established Chagas-related cardiomyopathy by visit
|
||
Subject analysis set title |
Nifurtimox 30 days: Chagas-related cardiomyopathy = No
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Serological response measured by two types of assays and ECG evaluation for signs of established Chagas-related cardiomyopathy by visit
|
||
Subject analysis set title |
Nifurtimox 30 days: Chagas-related cardiomyopathy = Missing
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Serological response measured by two types of assays and ECG evaluation for signs of established Chagas-related cardiomyopathy by visit
|
||
Subject analysis set title |
Historical Benznidazole 1998 - Sosa Estani et al. (1998)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
istorical Benznidazole 1998, publication from Sosa Estani et al. (1998), 4-year follow-up data.
|
||
Subject analysis set title |
Historical Benznidazole 1996, Andrade et al. (1996)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Historical Benznidazole 1996, publication from de Andrade et al. (1996), 3-year follow-up data.
|
|
|||||||||||||
End point title |
Part 1 - Percentage of sero-reduction or sero-conversion (cured subjects) | ||||||||||||
End point description |
Cure is defined as sero-reduction (in subjects ≥8 months to <18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a ≥20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.
Subjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).
For the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs for historical placebo control.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
At 12 months post-treatment
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Historical Cure Rates | ||||||||||||
Statistical analysis description |
Historical Cure Rates for Placebo Publication 1: De Andrade et al 1996. Age range (years): 7-12. Sero-conversion rate (95% CI) in placebo patients: 3/65 = 5% (1%, 13%) Publication 2: Sosa et al 1998. Age range (years): 6-12. Sero-conversion rate (95% CI) in placebo patients: 2/44 = 5% (1%, 16%). CI = confidence interval
|
||||||||||||
Comparison groups |
Nifurtimox 60 days / Arm 1 v Nifurtimox 30 days, then Placebo 30 days / Arm 2
|
||||||||||||
Number of subjects included in analysis |
330
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[1] | ||||||||||||
Method |
|||||||||||||
Parameter type |
Difference in cure rate | ||||||||||||
Point estimate |
14
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
3.7 | ||||||||||||
upper limit |
24.2 | ||||||||||||
Notes [1] - A direct comparison |
|
|||||||||
End point title |
Part 2 - Incidence rate of seronegative conversion in subjects received at least one dose of the 60-day nifurtimox treatment regimen. [2] | ||||||||
End point description |
Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay [IHA]) in subjects who were randomized and received at least one dose of the 60-day nifurtimox treatment regimen compared to an external control group of historical placebo patients with Chagas’ disease.
Incidence rate is the number of new cases of seronegative conversion over the study period (i.e., 4 years after end of nifurtimox treatment) divided by the person-time at risk. It was modelled using a Poisson distribution with a 2-sided 95% exact CI.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
4 years after end of treatment
|
||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics only |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Part 2 - Incidence rate of seronegative conversion in subjects who received at least one dose of the 30-day nifurtimox treatment regimen | ||||||||
End point description |
Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay [IHA]) in subjects who were randomized and received at least one dose of the 30-day nifurtimox treatment regimen.
Incidence rate is the number of new cases of seronegative conversion over the study period (i.e., 4 years after end of nifurtimox treatment) divided by the person-time at risk. It was modelled using a Poisson distribution with a 2-sided 95% exact CI.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
4 years after end of treatment
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 2 - Serological response and ECG signs of established Chagas-related cardiomyopathy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Summary of subjects by serological response and evidence of established Chagas-related cardiomyopathy as measured by electrocardiogram (ECG).
Evidence of established Chagas-related cardiomyopathy: Total
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
4 years after end of treatment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 + Part 2 - Serial reduction of optical density values measured by Total Purified Antigen ELISA | |||||||||||||||||||||||||||||||||||||||
End point description |
Summary and change from baseline of optical density values measured by total purified antigen ELISA.
|
|||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and 4 years after end of treatment
|
|||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 + Part 2 - Serial reduction of optical density values measured by Recombinant ELISA | |||||||||||||||||||||||||||||||||||||||
End point description |
Summary and change from baseline of optical density values measured by recombinant ELISA.
|
|||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and 4 years after end of treatment
|
|||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Part 1 - Number of subjects with Clinical signs/ symptoms of Chagas disease at Visit 1 | ||||||||||||
End point description |
The evaluation was based on clinical examinations.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At Visit 1 (before treatment started)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with Clinical signs/ symptoms of Chagas disease at Visit 3 | |||||||||||||||||||||
End point description |
The evaluation was based on clinical examinations.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Up to 7 days (Visit 3)
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Part 1 - Number of subjects with Clinical signs/ symptoms of Chagas disease at Visit 6 | |||||||||||||||
End point description |
The evaluation was based on clinical examinations.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Up to 30 days (Visit 6)
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with Clinical signs/ symptoms of Chagas disease at Visit 8 | |||||||||||||||||||||
End point description |
The evaluation was based on clinical examinations.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Up to 60 days (Visit 8; end of treatment)
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Part 1 - Number of subjects with Clinical signs/ symptoms of Chagas disease at Visit 9 | ||||||||||||
End point description |
The evaluation was based on clinical examinations.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 90 days (Visit 9 post-treatment)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Part 1 - Number of subjects with Clinical signs/ symptoms of Chagas disease at Visit 10 | ||||||||||||
End point description |
The evaluation was based on clinical examinations.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 240 days (Visit 10 post-treatment)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Part 1 - Number of subjects with Clinical signs/ symptoms of Chagas disease at Visit 11 | ||||||||||||
End point description |
The evaluation was based on clinical examinations.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with positive results in concentration test for T. cruzi (for subjects <8 months of age) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 90 days (Visit 9 post-treatment)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with a positive serological response using non-conventional enzyme-linked immunosorbent assay-F29 (ELISAF29) test | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with positive quantitative polymerase chain reaction (qPCR) results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Part 1 - Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | |||||||||||||||
End point description |
TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
up to 7 days after last application of study drug
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
Part 2 - Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | ||||||||||||||||||||||||||||||
End point description |
TEAEs comprised events which first occurred or worsened at study start up to end of study in part 2.
In Part 2, only AEs considered at least possibly related to nifurtimox (administered in part 1) and those caused by protocol-related procedures were reported.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
up to 3 years after start of study part 2
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with treatment-emergent high blood chemistry abnormalities by treatment | ||||||||||||||||||||||||||||||||||||||||||
End point description |
The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with treatment-emergent low blood chemistry abnormalities by treatment | ||||||||||||||||||||||||||||||||||||||||||
End point description |
The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with treatment-emergent high hematology abnormalities by treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Number of subjects with treatment-emergent low hematology abnormalities by treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Part 1 - Number of subjects with treatment-emergent high coagulation abnormalities by treatment | ||||||||||||||||||
End point description |
The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Part 1 - Number of subjects with treatment-emergent low coagulation abnormalities by treatment | ||||||||||||||||||
End point description |
The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Part 1 - Number of subjects with abnormal Urinalysis findings considered as clinically significant or reported as Adverse Events (AEs) | ||||||||||||
End point description |
Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin β, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Part 1 - Number of subjects with abnormal ECG findings considered as clinically significant by investigators | ||||||||||||
End point description |
Clinical significance of abnormal ECG was based on the judgement of the investigator
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Mean changes in vital signs (Systolic Blood Pressure) between the treatment groups from baseline | ||||||||||||||||||||||||||||||||||||
End point description |
Systolic Blood Pressure
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Mean changes in vital signs (Diastolic Blood Pressure) between the treatment groups from baseline | ||||||||||||||||||||||||||||||||||||
End point description |
Diastolic Blood Pressure
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Mean changes in vital signs (Respiratory Rate) between the treatment groups from baseline | ||||||||||||||||||||||||||||||||||||
End point description |
Respiratory Rate
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Mean changes in vital signs (Heart Rate) between the treatment groups from baseline | ||||||||||||||||||||||||||||||||||||
End point description |
Heart Rate
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Mean changes in vital signs (Body Temperature) between the treatment groups from baseline | ||||||||||||||||||||||||||||||||||||
End point description |
Temperature
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Part 1 - Nifurtimox concentration over time in plasma at Visit 2 | |||||||||||||||||||||||||||
End point description |
Measured in sub-population. 00000 = data not available.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
At Visit 2 (Day 1): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Part 1 - Nifurtimox concentration over time in plasma at Visit 3 | |||||||||||||||||||||||||||
End point description |
Measured in sub-population. 00000 = data not available.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
At Visit 3 (Day 7): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Part 1 - Nifurtimox concentration over time in plasma at Visit 6 | |||||||||||||||||||||||||||
End point description |
Measured in sub-population. 00000 = data not available.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
At Visit 6 (Day 30): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Part 1 - Nifurtimox concentration over time in plasma at Visit 8 | |||||||||||||||||||||||||||
End point description |
Measured in sub-population. 00000 = data not available.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
At Visit 8 (Day 60): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Part 1: Number of subjects cured with 60-day regimen compared with historical active control (benznidazole) [3] | ||||||||||||
End point description |
This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control.
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Descriptive statistics only |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Relationship of conventional serology (total purified antigen ELISA) and qPCR testing by Visit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Using frequencies of matches and mismatches to assess agreement
Reactive = Reac ELISA
Detectable = Detec qPCR
Non-reactive = Nonreac ELISA
Non-detectable = Nondetec qPCR
Non evaluable = Noneval qPCR
qPCR Missing = Miss qPCR
Missing conventional testing = Miss ELISA
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [4] - Nifurtimox 60 days with Reac ELISA and Detec qPCR [5] - Nifurtimox 60 days with Reac ELISA and Nondetec qPCR [6] - Nifurtimox 60 days with Nonreac ELISA and Detec qPCR [7] - Nifurtimox 60 days with Nonreac ELISA and Nondetec qPCR [8] - Nifurtimox 60 days with Reac ELISA and Non evaluable qPCR [9] - Nifurtimox 60 days with Reac ELISA and missing qPCR [10] - Nifurtimox 30 days with Reac ELISA and Detec qPCR [11] - Nifurtimox 30 days with Reac ELISA and Nondetec qPCR [12] - Nifurtimox 30 days with Nonreac ELISA and Detec qPCR [13] - Nifurtimox 30 days with Nonreac ELISA and Nondetec qPCR [14] - Nifurtimox 30 days with Reac ELISA and Non evaluable qPCR [15] - Nifurtimox 30 days with Miss ELISA and Nondetec qPCR |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Relationship of conventional serology (total purified antigen ELISA) and non-conventional (ELISA-F29) serologic testing by visit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Using frequencies of matches and mismatches to assess agreement
Reactive = Reac ELISA
Reactive = Reac F29
Non-reactive = Nonreac ELISA
Non-reactive = Nonreac F29
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [16] - Nifurtimox 60 days with Reac ELISA and Reac F29 [17] - Nifurtimox 60 days with Reac ELISA and Nonreac F29 [18] - Nifurtimox 60 days with Nonreac ELISA and Reac F29 [19] - Nifurtimox 60 days with Nonreac ELISA and Nonreac F29 [20] - Nifurtimox 30 days with Reac ELISA and Reac F29 [21] - Nifurtimox 30 days with Reac ELISA and Nonreac F29 [22] - Nifurtimox 30 days with Nonreac ELISA and Reac F29g [23] - Nifurtimox 30 days Nonreac ELISA and Nonreac F29 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Relationship of conventional serology (recombinant ELISA) and non-conventional (ELISA-F29) serologic testing by visit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Using frequencies of matches and mismatches to assess agreement
Reactive = Reac ELISA
Reactive = Reac F29
Non-reactive = Nonreac ELISA
Non-reactive= Nonreac F29
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [24] - Nifurtimox 60 days Reac ELISA and Reac F29 [25] - Nifurtimox 60 days with Reac ELISA and Nonreac F29 [26] - Nifurtimox 60 days with Nonreac ELISA and Reac F29 [27] - Nifurtimox 60 days Nonreac ELISA and Nonreac F29 [28] - Nifurtimox 30 days with Reactive ConvReac ELISA and Reac F29 [29] - Nifurtimox 30 days with Reac ELISA and Nonreac F29 [30] - Nifurtimox 30 days with Nonreac ELISA and Reac F29 [31] - Nifurtimox 30 days with Nonreac ELISA and Nonreac F29 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Part 1 - Relationship of conventional serology (ELISA) to Indirect hemagglutination assay (IHA) results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Sero-reduction is defined as a => 20% reduction in optical density [OD]) using two conventional ELISA serology tests in subjects => 8 months to < 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects => 8 months to < 18 years of age at randomization; or reactive results in subjects < 8 months of age at randomization.
Non-reactive ELISA = Nonreac ELISA
Non-reactive IHA = Nonreac IHA
Reactive IHA decrease = Reac IHA dec
React IHA nochange = Reac IHA nochange
Reactive ELISA: seroreduction = Reac ELISA reduc
Reactive ELISA: others = Reac ELISA other
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [32] - Nonreac ELISA and Nonreac IHA [33] - Nonreac ELISA and Reac IHA dec [34] - Nonreac ELISA and Reac IHA nochange [35] - Reac ELISA and Nonreac IHA [36] - Reac ELISA reduc and Reac IHA dec [37] - Reac ELISA reduc and Reac IHA nochange [38] - Reac ELISA other and Nonreac IHA [39] - Reac ELISA other and Reac IHA dec [40] - Reac ELISA other and Reac IHA nochange [41] - Reac ELISA other and IHA missing |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
Part 1 - Relationship between conventional ELISA results in terms of Cure or No Cure and IHA results in all patients | ||||||||||||||||||||||||||||||
End point description |
Cure is defined as sero-reduction (in subjects => 8 months to < 18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a => 20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G [IgG] concentration measured by two conventional ELISA serology tests.
Cure = Cure
Non reactive/reactive decreasing = Nonreac/reac dec
Reactive non-decreasing = Reac nondec
No cure = No Cure
Missing IHA testing = IHA missing
|
||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||||
End point timeframe |
Up to 420 days (Visit 11 post-treatment)
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Notes [42] - ELISA Cure and IHA Nonreac/reac dec [43] - ELISA Cure and IHA Reac nondec [44] - ELISA No Cure and IHA results: Nonreac/reac dec [45] - ELISA No Cure and IHA Reac nondec [46] - ELISA No Cure and IHA missing |
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Part 1: From first application of study drug up to and including 7 days after last application of study drug
Part 2: first occurred or worsened at start 0f study part 2 up to 3 years.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Part 1: TEAS first occurred or worsened after first application of study drug up to 7 days after last application.
Part 2: only AEs considered at least possibly related to nifurtimox (administered in part 1) and those caused by protocol-related procedures were reported.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
20.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nifurtimox 30 days
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three timesdaily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nifurtimox 60 days
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 2% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
02 Apr 2015 |
- Text added to indicate that ECGs will be obtained at the time PK samples are collected when nifurtimox has reached Cmax or peak steady-state concentrations (i.e., at the 2 – 4 hour time point).
- Clarification of study objectives and efficacy variables regarding sero-reduction and sero-conversion; change in tests required for confirmation of Chagas’ disease (recombinant ELISA and total purified antigen ELISA).
- Baseline specimens for serological tests to be collected for diagnosis, and frozen as a subject control.
- Change in urine color to be reinforced to subjects at the visits where study drug is dispensed.
- Information about laboratory procedures, assay variability and cutoffs, and facilities to be used for all assays was added.
- A safety and compliance questionnaire/script (Phone Contact Form) for use by site staff when conducting the telephone assessments was added.
- For standardization of adverse event reporting, the terms “mild”, “moderate”, and “severe” were defined within the protocol.
- A telephone assessment at Day 14 was added.
- Measurement of ECGs will be optional assessments for subjects < 5 years of age, and required for subjects 5 years of age and older.
- A neurological examination to be performed at the time of each physical examination in the study was added.
- Detailed procedures regarding follow-up on all subjects who prematurely discontinue study drug was added.
- Monitoring of treatment compliance was included in the Visit 6 (Day 30) study assessments to be conducted via telephone; this is reflected in the Phone Contact Form.
- A Phone Contact Form was developed and added as an appendix to the protocol.
- A Subject Diary was developed and added as an appendix to the protocol. |
||
19 Oct 2015 |
- To address FDA comments regarding handling of the analyses of data for the primary efficacy endpoint.
- To provide textual clarifications resulting from comments received from Ethics Committees and ex-US Health Authorities. - Overall editorial corrections and clarifications. |
||
07 Apr 2016 |
- To delete a phrase “and ECG abnormalities” which was added in error to amendment 2. |
||
15 Nov 2016 |
- To implement a PK subject diary which will allow PK subjects to record the meals consumed with study drug administration.
- Clarifying editorial changes were made |
||
12 Oct 2017 |
- To introduce an additional test (Immunofluorescent antibody,
IFA), which would validate the current ELISA test results, as requested by FDA. This test will be carried out at Visit 1 and Visit 11 using random back-up samples from the study
subjects. |
||
20 Dec 2017 |
- To replace the immunofluorescent antibody (IFA) test
introduced via Amendment 5 by the indirect hemagglutination assay (IHA).
- Use of another serological test such as IFA or IHA was requested by FDA to validate the current ELISA test results. This test will be carried out at Visit 1 and Visit 11 using random
back-up samples from the study subjects. |
||
11 May 2018 |
- To satisfy FDA’s request to “further describe and verify the
clinical benefit of nifurtimox” according to the FDA meeting minutes of the Type C meeting in August 2017 by following the subjects in Study 16027 for a reasonable amount of time to
demonstrate reversion of serology to negative.
- Changes include extending the current Study 16027 with the long-term follow-up (LTFU), and detailed study design and procedures for this LTFU considering FDA’s recommendations
to the detailed study concept for the LTFU received in March 2018. |
||
23 Jul 2019 |
To incorporate feedback received from study site personnel at
the investigator meeting for part 2 of the study in APR 2019. None of the changes implemented in this amendment impact the benefit-risk evaluation of the study. |
||
18 Oct 2019 |
- To incorporate feedback received from the FDA on 19 SEP 2019. It will allow subjects who were randomized and received at least one dose of their assigned nifurtimox treatment regimen and who are otherwise eligible to participate in the long-term follow-up portion of the study (Part 2, CHICO SECURE), regardless of subsequent treatment for Chagas’ disease. None of the changes implemented in this
amendment impact the benefit-risk evaluation of the study. |
||
03 Nov 2020 |
- To incorporate feedback received from the FDA on 10 JUL 2020. The Agency requested inclusion of non-conventional ELISA in Part 2 (CHICO SECURE) of the study and that antibody titers by serial dilution be obtained for all available serum samples. None of the changes implemented in this
amendment impacted the benefit-risk evaluation of the study. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Abnormal findings on neurological examination by physical examination after Screening will be documented as AEs. | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/33412557 |